This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00800176
First received: December 1, 2008
Last updated: July 26, 2016
Last verified: July 2016
December 1, 2008
July 26, 2016
January 2009
October 2009   (Final data collection date for primary outcome measure)
Absolute change in HbA1c [ Time Frame: From baseline to end of treatment period ]
Same as current
Complete list of historical versions of study NCT00800176 on ClinicalTrials.gov Archive Site
  • Absolute change in parameters of glycemic control [ Time Frame: From baseline to end of treatment period ]
  • Absolute change in body weight, waist-to-hip ratio, waist circumference [ Time Frame: From baseline to end of treatment period ]
  • Adverse events, laboratory parameters, vital signs [ Time Frame: Throughout study ]
Same as current
Not Provided
Not Provided
 
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
A Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled 12-week Study to Investigate Glycemic Parameters of Efficacy, Safety/ Tolerability and Pharmacokinetics of Five Dose Levels of RO4998452 in Patients With Type 2 Diabetes Mellitus
This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus. Patients will be randomized to one of 6 groups to receive RO4998452 at doses of 2.5mg, 5mg, 10mg, 20mg or 40mg po daily, or placebo daily. Patients pre-treated with stable metformin will continue to take their usual dose of metformin throughout the study.The anticipated time on study treatment is <=3 months
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Diabetes Mellitus Type 2
  • Drug: Placebo
    po daily for 12 weeks
  • Drug: RO4998452
    2.5mg po daily for 12 weeks
  • Drug: RO4998452
    5mg po daily for 12 weeks
  • Drug: RO4998452
    10mg po daily for 12 weeks
  • Drug: RO4998452
    20mg po daily for 12 weeks
  • Drug: RO4998452
    40mg po daily for 12 weeks
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: RO4998452 10mg
    Intervention: Drug: RO4998452
  • Experimental: RO4998452 2.5mg
    Intervention: Drug: RO4998452
  • Experimental: RO4998452 20mg
    Intervention: Drug: RO4998452
  • Experimental: RO4998452 40mg
    Intervention: Drug: RO4998452
  • Experimental: RO4998452 5mg
    Intervention: Drug: RO4998452
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
405
October 2009
October 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • adult patients, 18-75 years of age;
  • type 2 diabetes, diagnosed for >=3 months;
  • either treated with diet, exercise and stable metformin, or with diet and exercise alone.

Exclusion Criteria:

  • type 1 diabetes mellitus;
  • currently or within 2 months prior to screening treated with an oral or injectable anti-diabetic agent except stable doses of metformin;
  • currently or within 6 months prior to screening treated with any PPARgamma agonist;
  • uncontrolled hypertension;
  • significant pre-diagnosed diabetic complications requiring treatment.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Brazil,   Canada,   Germany,   Hong Kong,   Japan,   Latvia,   Mexico,   Romania,   Russian Federation,   Spain,   United States
China
 
NCT00800176
BC21587
2008-001249-24
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP